| Filing date | Form | Description | Filing Group | View |
|---|---|---|---|---|
| DEFA14A | Additional proxy soliciting materials - definitive |
Proxy Filings
|
||
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
| DEFA14A | Additional proxy soliciting materials - definitive |
Proxy Filings
|
||
| DEF 14A | Official notification to shareholders of matters to be brought to a vote ("Proxy") |
Proxy Filings
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
| ARS | An annual report to security holders |
Annual Filings
|
||
| 8-K/A | Amendment to a previously filed 8-K |
Current Reports
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
| PRE 14A | A preliminary proxy statement providing notification matters to be brought to a vote |
Proxy Filings
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
| 10-K | Annual report which provides a comprehensive overview of the company for the past year |
Annual Filings
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA |
Data provided by Kaleidoscope.
GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.
